https://orcid.org/0000-0003-0338-1331
Citations (10)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Robyn Kendall, Alan A Martin, Dhvani Shah, Soham Shukla, Chris Compton & Afisi S Ismaila. (2023) Cost-Effectiveness of Single-Inhaler Triple Therapy (FF/UMEC/VI) versus Tiotropium Monotherapy in Patients with Symptomatic Moderate-to-Very Severe COPD in the UK. International Journal of Chronic Obstructive Pulmonary Disease 18, pages 1815-1825.
Read now
Read now
Juan Antonio Trigueros, Noé Garin, Adolfo Baloira, Susana Aceituno, Ana Calvo, Miriam Prades, Carolina Touron, Anisia Martínez & Covadonga Torres. (2022) Cost-Effectiveness Analysis of Triple Therapy with Budesonide/ Glycopyrronium/ Formoterol Fumarate versus Dual Therapy in Patients with Chronic Obstructive Pulmonary Disease in Spain. International Journal of Chronic Obstructive Pulmonary Disease 17, pages 2905-2917.
Read now
Read now
David MG Halpin, Robyn Kendall, Soham Shukla, Alan Martin, Dhvani Shah, Dawn Midwinter, Kai M Beeh, Janwillem WH Kocks, Paul W Jones, Chris Compton, Nancy A Risebrough & Afisi S Ismaila. (2022) Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID Trial. International Journal of Chronic Obstructive Pulmonary Disease 17, pages 2745-2755.
Read now
Read now
Victoria Federico Paly, Laura Amanda Vallejo-Aparicio, Alan Martin, José Luis Izquierdo, Juan Antonio Riesco, Juan José Soler-Cataluña, Catarina Abreu, Chandroday Biswas & Afisi S Ismaila. (2022) Cost-Effectiveness of Once-Daily Single-Inhaler COPD Triple Therapy in Spain: IMPACT Trial. International Journal of Chronic Obstructive Pulmonary Disease 17, pages 3097-3109.
Read now
Read now
Francesco Lapi, Ettore Marconi, Francesco Paolo Lombardo, Claudio Micheletto & Claudio Cricelli. (2022) Variation in costs due to virtual switching from free- to fixed-triple LABA/LAMA/ICS combinations among COPD patients: an analysis using a primary care database. Current Medical Research and Opinion 38:11, pages 1997-2001.
Read now
Read now
Rezwanul Hasan Rana, Khorshed Alam, Syed Afroz Keramat & Jeff Gow. (2022) Cost-effectiveness of single-inhaler triple therapy for patients with severe COPD: a systematic literature review. Expert Review of Respiratory Medicine 16:10, pages 1067-1084.
Read now
Read now
Mario Cazzola, Paola Rogliani, Luigino Calzetta, Josuel Ora & Maria Gabriella Matera. (2022) A single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol for the treatment of COPD. Expert Review of Clinical Pharmacology 15:3, pages 269-283.
Read now
Read now
Articles from other publishers (3)
Emanuela Resta, Giulia Scioscia, Donato Lacedonia, Carla Maria Irene Quarato, Francesco Panza, Onofrio Resta, Giorgia Lepore, Enrico Buonamico, Valentina Di Lecce, Giovanna Elisiana Carpagnano, Maria Pia Foschino Barbaro & Noemi Rossi. (2022) Economic impact of implementing prescription of single-inhaler triple therapies versus current multiple-inhaler triple therapies for COPD in the Apulia Region. BMC Health Services Research 22:1.
Crossref
Crossref
Alan Martin, Dhvani Shah, Kerigo Ndirangu, Glenn A. Anley, Gabriel Okorogheye, Melanie Schroeder, Nancy Risebrough & Afisi S. Ismaila. (2022) Is single-inhaler triple therapy for COPD cost-effective in the UK? The IMPACT trial. ERJ Open Research 8:1, pages 00333-2021.
Crossref
Crossref
Yikang Zhou, Enwu Long, Qian Xu, Lei Wang, Xuehua Jiang & Ming Hu. (2021) Cost-Effectiveness Analysis of Triple Combination Preparations in the Treatment of Moderate-to-Severe Chronic Obstructive Pulmonary Disease. Frontiers in Public Health 9.
Crossref
Crossref